MidWestOne Financial Group’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,140
Closed -$615K 283
2023
Q3
$615K Sell
3,140
-378
-11% -$77.6K 0.14% 167
2023
Q2
$740K Buy
3,518
+308
+10% +$61.3K 0.16% 165
2023
Q1
$648K Buy
3,210
+1,267
+65% +$287K 0.15% 164
2022
Q4
$423K Buy
1,943
+445
+30% +$97.2K 0.09% 193
2022
Q3
$295K Buy
+1,498
New +$323K 0.08% 192

Other funds holding CRL

MidWestOne Financial Group's CRL Position: Q4 2023 in Review

MidWestOne Financial Group sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 3,140 shares — an estimated $615K sold.

MidWestOne Financial Group first reported a position in CRL in Q3 2022 and held it in 5 quarters. The position peaked at $740K in Q2 2023. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

  • MidWestOne Financial Group reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
  • MidWestOne Financial Group sold 3,140 Charles River Laboratories shares in Q4 2023, an estimated $615K.
  • MidWestOne Financial Group first reported a position in Charles River Laboratories in Q3 2022 and held it in 5 quarters.
  • MidWestOne Financial Group's Charles River Laboratories position peaked at $740K in Q2 2023.
  • 634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on MidWestOne Financial Group's 13F filing for Q4 2023, filed 15 Feb 2024.